BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (AMRX) (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a long-acting subcutaneous risperidone injection for the treatment of schizophrenia in adults.
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of adverse events were similar in both dosing ...
The RISE study 7 was a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of risperidone extended-release injectable suspension for subcutaneous use as a ...
The approval was based on data from adequate and well-controlled studies with risperidone long-acting injection (intramuscular). The Food and Drug Administration (FDA) has approved Rykindo ® ...
Rykindo ® is a bi-weekly long-acting risperidone injection and is the first innovative therapy from Luye Pharma's Central Nervous System (CNS) product portfolio to be marketed in the United States.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results